Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemolizumab in moderate-to-severe atopic dermatitis (ARCADIA 1)
NCT03985943Phase 3Completed
- Sponsor
- Galderma
- Start
- Jun 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Nemolizumab + TCS with Placebo + TCS (2 arms). Primary endpoints: Investigator's Global Assessment Success at 16 weeks and 75% Improvement in Eczema Area and Severity Index at 16 weeks. Started Jun 2019; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03985943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03985943.